Journal of Antimicrobial Chemotherapy (2002) 50, 161-169
© 2002 The British Society for Antimicrobial Chemotherapy
Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low
Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
Received 13 December 2001; returned 8 March 2002; revised 3 May 2002; accepted 17 May 2002
Populations defective in mismatch repair that exhibit elevated mutation frequencies to antibiotic resistance have been reported amongst pathogenic Gram-negative bacteria. Whether such mutators occur widely in clinical isolates of Gram-positive species, and in important pathogens such as Staphylococcus aureus, is unknown. Insertional inactivation of the mutS gene of S. aureus RN4220 by targeted plasmid integration produced a strain with mutation frequencies for antibiotic resistance up to 78-fold greater than those exhibited by RN4220, thereby providing proof of the concept that staphylococcal mutators could arise. Subsequently, 493 clinical S. aureus isolates were examined for the presence of mutators. However, no strain exhibited a 
10-fold increase in mutation frequency compared with laboratory strain 8325-4. Detailed phenotypic and genotypic analysis of vancomycin-intermediate S. aureus strain Mu50 was performed, since the published genome sequence of this organism suggests that mutS is inactive as a result of a frameshift. However, elevated mutation frequencies were not observed in Mu50, and re-sequencing of a portion of mutS from this strain indicated that this gene was intact. Transient increases in mutation frequency during the stationary phase of growth occur in other bacteria, although no such increases were observed in S. aureus. We conclude that neither permanent increases in the basal mutation frequency, nor transient increases in mutation frequency under starvation, are likely to play a significant role in the development of antibiotic resistance in S. aureus.
* Corresponding author. Tel: +44-113-233-5604; Fax: +44-113-233-5638; E-mail: i.chopra{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. P. Howden, J. K. Davies, P. D. R. Johnson, T. P. Stinear, and M. L. Grayson Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications Clin. Microbiol. Rev., January 1, 2010; 23(1): 99 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Besier, J. Zander, B. C. Kahl, P. Kraiczy, V. Brade, and T. A. Wichelhaus The Thymidine-Dependent Small-Colony-Variant Phenotype Is Associated with Hypermutability and Antibiotic Resistance in Clinical Staphylococcus aureus Isolates Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2183 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Marcobal, D. A. Sela, Y. I. Wolf, K. S. Makarova, and D. A. Mills Role of Hypermutability in the Evolution of the Genus Oenococcus J. Bacteriol., January 15, 2008; 190(2): 564 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, M. Warner, S. Mushtaq, S. North, and N. Woodford In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1112 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. C. Hall and S. K. Henderson-Begg Hypermutable bacteria isolated from humans - a critical analysis. Microbiology, September 1, 2006; 152(Pt 9): 2505 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-L. Prunier and R. Leclercq Role of mutS and mutL Genes in Hypermutability and Recombination in Staphylococcus aureus J. Bacteriol., May 15, 2005; 187(10): 3455 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Trong, A.-L. Prunier, and R. Leclercq Hypermutable and Fluoroquinolone-Resistant Clinical Isolates of Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2005; 49(5): 2098 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Koehl, A. Muthaiyan, R. K. Jayaswal, K. Ehlert, H. Labischinski, and B. J. Wilkinson Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3749 - 3757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muthaiyan, R. K. Jayaswal, and B. J. Wilkinson Intact mutS in Laboratory-Derived and Clinical Glycopeptide-Intermediate Staphylococcus aureus Strains Antimicrob. Agents Chemother., February 1, 2004; 48(2): 623 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Willems, J. Top, D. J. Smith, D. I. Roper, S. E. North, and N. Woodford Mutations in the DNA Mismatch Repair Proteins MutS and MutL of Oxazolidinone-Resistant or -Susceptible Enterococcus faecium Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3061 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. O'Neill, I. Chopra, G. Bierbaum, A. Reipert, and F. Schaaff Lack of Evidence for Involvement of Hypermutability in Emergence of Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1484 - 1485. [Full Text] [PDF]
|
|